Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

References

• Matasar M J, Ritchie E K, Consedine N, Magai C, Neugut A I. Incidence rates of the major leukemia subtypes among US hispanics, blacks, and non-Hispanic whites. Leuk Lymphoma 2006; 47: 2365–2370
   PubMed Web of Science ®Google Scholar
• Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894–1907
   PubMed Web of Science ®Google Scholar
• Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18–34
   PubMed Web of Science ®Google Scholar
• Wong L, Suh D Y, Frankel A E. Toxin conjugate therapy of cancer. Semin Oncol 2005; 32: 591–595
   PubMed Web of Science ®Google Scholar
• Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 2007; 7: 11–17
   PubMed Web of Science ®Google Scholar
• Frankel A E, Ramage J, Latimer A, Feely T, Delatte S, Hall P, et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for Phase I clinical trials. Protein Expr Purif 1999; 16: 190–201
   PubMed Web of Science ®Google Scholar
• Frankel A E, Powell B L, Hall P D, Case L D, Kreitman R J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8: 1004–1013
   PubMed Web of Science ®Google Scholar
• Westcott M M, Abi-Habib R J, Cohen K A, Willingham M C, Liu S, Bugge T H, et al. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther 2004; 3: 1681–1689
   PubMed Web of Science ®Google Scholar
• Nitsche A, Junghahn I, Thulke S, Aumann J, Radonic A, Fichtner I, et al. Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice. Stem Cells 2003; 21: 236–244
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3R alpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis. Blood 2002; 100: 2980–2988
   PubMed Web of Science ®Google Scholar
• Jordan C T, Upchurch D, Szilvassy S J, Guzman M L, Howard D S, Pettigrew A L, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784
   PubMed Web of Science ®Google Scholar
• Budel L M, Touw I P, Delwel R, Clark S C, Lowenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 1989; 74: 565–571
   PubMed Web of Science ®Google Scholar
• Munoz L, Nomdedeu J F, Lopez O, Carnicer M J, Bellido M, Aventin A, et al. Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies. Mol Hematol 2001; 86: 1261–1269
   PubMed Web of Science ®Google Scholar
• Riccioni R, Rossini A, Calabro L, Diverio D, Pasquini L, LoCoco F, et al. Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. Leuk Lymphoma 2004; 45: 1511–1517
   PubMed Web of Science ®Google Scholar
• Colotta F, Bussolino F, Polentarutti N, Guglie L M, Etti A, Sironi M, et al. Differential expression of the common beta and specific alpha chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells. Exp Cell Res 1993; 206: 311–317
   PubMed Web of Science ®Google Scholar
• Frankel A E, Ramage J, Kiser M, Alexander R, Kucera G, Miller M S. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000; 13: 575–581
   PubMedGoogle Scholar
• Frankel A E, McCubrey J A, Miller M S, Delatte S, Ramage J, Kiser M, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14: 576–585
   PubMed Web of Science ®Google Scholar
• Alexander R L, Ramage J, Kucera G L, Caliguiri M A, Frankel A E. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001; 25: 875–881
   PubMed Web of Science ®Google Scholar
• Alexander R L, Kucera G L, Klein B, Frankel A E. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconj Chem 2000; 11: 564–568
   PubMed Web of Science ®Google Scholar
• Black J H, McCubrey J A, Willingham M C, Ramage J, Hogge D E, Frankel A E. Diphtheria toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003; 17: 155–159
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Frankel A E, Alexander R L, Gerhard B, Hogge D E. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002; 62: 1730–1736
   PubMed Web of Science ®Google Scholar
• Yalcintepe L, Frankel A E, Hogge D E. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 2006; 108: 3530–3537
   PubMed Web of Science ®Google Scholar
• Urieto J O, Liu T F, Black J H, Cohen K A, Hall P D, Willingham M C, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Exp Purif 2004; 33: 123–133
   PubMed Web of Science ®Google Scholar
• Cohen K A, Liu T F, Cline J M, Wagner J D, Hall P D, Frankel A E. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother 2005; 54: 799–806
   PubMed Web of Science ®Google Scholar
• Hall P D, Virella G, Beckham W, Frankel A E. Adult AML patients treated with DTGM diphtheria fusion toxin do not have neutralizing antibodies before or after the first treatment course. Clin Immunol 2001; 100: 191–197
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, William C L, Estey E H, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674
   PubMed Web of Science ®Google Scholar
• Smallshaw J E, Ghetie V, Rizo J, Fulmer J R, Trahan L L, Ghetie M A, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003; 21: 387–391
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A E, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–388
   PubMed Web of Science ®Google Scholar
• Filpula D, Yang K, Bau A, Hassan R, Xiang L, Zhang Z, et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconj Chem 2007; 18: 773–784
   PubMed Web of Science ®Google Scholar
• Hogge D E, Valcintepe L, Wong S H, Gerhard B, Frankel A E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 2006; 12: 1284–1291
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Biffoni M, Diverio D, LoCoco F, Foa R, et al. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005; 106: 2527–2529
   PubMed Web of Science ®Google Scholar
• Jordan C T. Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2005; 2: 224–225
   PubMedGoogle Scholar
• Liu T F, Urieto J O, Moore J E, Miller M S, Lowe A C, Thorburn A, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 2004; 32: 277–281
   PubMed Web of Science ®Google Scholar
• Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30: 607–613
   PubMed Web of Science ®Google Scholar
• Hogge D E, Feuring-Buske M, Gerhard B, Frankel A E. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res 2004; 28: 1221–1226
   PubMed Web of Science ®Google Scholar
• Kim C N, Bhalla K, Kreitman R J, Willingham M C, Hall P D, Tagge E P, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res 1999; 23: 527–538
   PubMed Web of Science ®Google Scholar
• Frankel A E, Hall P D, McLain C, Safa A R, Tagge E P, Kreitman R J. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconj Chem 1998; 9: 490–496
   PubMed Web of Science ®Google Scholar
• Kreitman R J, Squires D R, Stetler-Stevenson M, Noel P, FitzGerald D J, Wilson W H, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719–6729
   PubMed Web of Science ®Google Scholar